Anand Singh

7PUBLICATIONS
116CO-AUTHORS
Molecular targetsCancer geneticsGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 29, 2026
Specific F1 ATP synthase inhibition delivers transient mitochondrial stress for selective targeting of acute myeloid leukemia.

|May 08, 2026
Reprogramming of Cellular Plasticity via ETS and MYC Core-Regulatory Circuits during Response to MAPK Inhibition in BRAF-Mutant Colorectal Cancer.

|Sep 13, 2024
Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer.

Hey Min Lee, Ajay Kumar Saw, Van K Morris

|Sep 11, 2024
BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML.

Bijender Kumar, Anand Singh, Rafet Basar

|Feb 16, 2024
Tsyn-Seq: a T-cell Synapse-Based Antigen Identification Platform.

Yimei Jin, Takahiko Miyama, Alexandria Brown

|Feb 11, 2023
Epigenetic Perspective of Immunotherapy for Cancers.

Sunita Keshari, Praveen Barrodia, Anand Kamal Singh

Pageof 2

Frequent Collaborators

5 joint publications

Kunal Rai

3 joint publications

Abhinav K Jain

2 joint publications

Alexey Sorokin

2 joint publications

Emre Arslan